Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Merck & Co. reveals new prodrugs of fibrinogen receptor antagonists

March 23, 1998

Antiplatelet agents reported by researchers at Nippon Steel

March 20, 1998

Modified factor VII interrupts the coagulation cascade

March 18, 1998

Novartis describes new thrombin inhibitors

March 17, 1998

Centocor completes acquisition of reteplase

March 16, 1998

Improved anticoagulants in development at Gyogyszerkutato Intezet

March 16, 1998

Treatment of acute coronary syndromes by thrombin inhibition

March 16, 1998

Boehringer Ingelheim discloses new antiplatelet agents

March 13, 1998

Antithrombotics developed at Warner-Lambert

March 12, 1998

First Rx for HIT type II approved in U.S.

March 10, 1998

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...